Vaxcyte, Inc. (PCVX) Announces Progress in its VAX-31 Infant Vaccine Study

Vaxcyte, Inc. (NASDAQ:PCVX) is one of the Oversold Growth Stocks to Buy According to Analysts. On September 3, Vaxcyte, Inc. (NASDAQ:PCVX) announced progress in its VAX-31 infant vaccine study for Phase 2. The drug has moved to the third and final dose-finding study after protocol changes that added a new optimized dose arm and removed the low-dose arm, with about 900 infants to be enrolled.

It compares VAX-31 to the current standard vaccine, Prevnar 20, and the company expects key safety, tolerability, and immune response data by mid-2027. CEO of Vaxcyte, Inc. (NASDAQ:PCVX), Grant Pickering, emphasized that the Optimized Dose could prompt stronger immune responses. VAX-31 aims to cover about 92% of invasive pneumococcal disease and 93% of acute otitis media cases in US children under five.

Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage vaccine company focused on developing innovative conjugate and protein vaccines to prevent or treat bacterial infectious diseases.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.